Claude Ambroise
Pfizer (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Cholinesterase and Neurodegenerative Diseases, Computational Drug Discovery Methods, Statistical Methods in Clinical Trials, French Urban and Social Studies
Most-Cited Works
- → The B73 Maize Genome: Complexity, Diversity, and Dynamics(2009)4,168 cited
- → Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors(2016)76 cited
- → Spirocyclic Sulfamides as β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer’s Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies To Identify Centrally Efficacious Inhibitors(2012)60 cited
- → Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation(2018)42 cited
- → Discovery of Small-Molecule CD33 Pre-mRNA Splicing Modulators(2022)16 cited
- → Tool Compounds Robustly Increase Turnover of an Artificial Substrate by Glucocerebrosidase in Human Brain Lysates(2015)13 cited
- → P4–288: Effect of A673T mutation on APP processing by BACE1 and its significance for Alzheimer's disease therapeutic research(2013)1 cited
- → P3‐313: Using single‐point pharmacokinetic/pharmacodynamic (PK/PD) analyses to support early discovery of inhibitors of β‐site APP cleaving enzyme 1 (BACE1)(2010)
- → P4–278: Clinical gamma‐secretase inhibitors (GSIs) alter beta‐amyloid 40/42 ratio in brain and show CSF beta‐amyloid rebound in vivo(2013)
- → P2–379: Disconnect between brain and CSF drug exposure and beta‐amyloid levels following BACE inhibition(2013)